<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123743</url>
  </required_header>
  <id_info>
    <org_study_id>00001</org_study_id>
    <nct_id>NCT04123743</nct_id>
  </id_info>
  <brief_title>Efficacy of Extract of Trigonella Foenum-graceum as Topical Phytoestrogen in Skin Aging Treatment of Post Menopausal Women</brief_title>
  <official_title>Efficacy of Extract of Trigonella Foenum-graceum (Fenugreek) as Topical Phytoestrogen in Skin Aging Treatment of Post Menopausal Women : A Study of COL1A1, COL3A1, Skin Thickness, and Skin Wrinkles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skin is subjected to intrinsic aging and extrinsic aging. Intrinsic aging is influenced by
      genetic and hormonal factors. Estrogen has significant role in modulating skin physiology. In
      post menopausal women, skin aging is accelerated because of hypoestrogenism. Administration
      of estrogen can delay the process of skin aging. Phytoestrogens are estrogen-like compounds
      which can be found naturally in plants. The investigators intend to study the efficacy of
      Trigonella foenum-graceum extract as topical phytoestrogen in skin aging treatment of post
      menopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this double-blinded unmatched randomized controlled trial, the investigators intend to
      study the efficacy of Trigonella foenum-graceum extract as topical phytoestrogen in skin
      aging treatment of post menopausal women. The investigators have gathered 21 participants
      that will be divided into 2 groups, experimental group and control group. Experimental group
      will get treatment with topical cream containing Trigonella foenum-graceum extract, while
      control group will get treatment with placebo cream.

      The study will be held in esthetic cluster, Kencana Cipto Mangunkusumo Hospital, and
      radiology cluster, Kencana Cipto Mangunkusumo Hospital from August 2019 until November 2019.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Anticipated">November 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The participants will be divided into 2 groups, experimental group and control group. Experimental group will get intervention with topical cream containing Trigonella foenum-graceum extract, while control group will get intervention with placebo topical cream. Both experimental and control group will receive Wardah brand facial wash and Parasol sunscreen SPF 33 as part of the assigned intervention as well.The participants will undergo the assigned intervention for 12 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinding is done to the participants, care providers, investigator, and outcomes assessor in every stage of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale for Forehead Wrinkles</measure>
    <time_frame>Change from initial visit VAS at 12 weeks</time_frame>
    <description>Visual Analogue Scale (VAS) to measure wrinkles in the forehead region (Scale 0-8, with 0-2 categorized as mild wrinkling, 3-5 categorized as moderate wrinkling, and 6-8 categorized as severe wrinkling)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale for Crow's Feet Wrinkles</measure>
    <time_frame>Change from initial visit VAS at 12 weeks</time_frame>
    <description>Visual Analogue Scale (VAS) to measure wrinkles in crow's feet region (Scale 0-6), with 0-2 categorized as mild wrinkling, 3-4 categorized as moderate wrinkling, and 5-6 categorized as severe wrinkling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale for Nasolabial Wrinkles</measure>
    <time_frame>Change from initial visit VAS at 12 weeks</time_frame>
    <description>Visual Analogue Scale (VAS) to measure wrinkles in nasolabial region (Scale 0-6), with 0-2 categorized as mild wrinkling, 3-4 categorized as moderate wrinkling, and 5-6 categorized as severe wrinkling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Resolution Ultrasound</measure>
    <time_frame>Change from initial visit dermis thickness at 12 weeks</time_frame>
    <description>High resolution ultrasound examination in bilateral cheek region to determine dermis thickness (in milimeter).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Skin Aging</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will be given topical cream containing Trigonella foenum-graceum extract, Wardah brand facial wash, and Parasol sunscreen SPF 33.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control / placebo group will be given placebo topical cream, Wardah brand facial wash, and Parasol sunscreen SPF 33</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trigonella foenum-graceum extract topical cream</intervention_name>
    <description>Topical cream containing Trigonella foenum-graceum extract</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Facial Wash</intervention_name>
    <description>Wardah brand facial wash</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sunscreen Cream</intervention_name>
    <description>Parasol sunscreen cream SPF 33</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo topical cream</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with minimum 2 years post menopausal and maximum 8 years post menopausal

          -  Have skin aging problems that manifested as wrinkles on forehead, crow's feet, and
             nasolabial fold region

          -  Estradiol level &lt; 30 pg/mL

          -  Willing to terminate the routine use of facial cream or treatment during the study
             duration and at least for 30 days before the study commence

          -  Willing to follow the study protocol and sign the informed consent

        Exclusion Criteria:

          -  Dermatitis in the region of face

          -  Using oral/topical hormonal supplement in the last 12 months

          -  Using products containing retinoic acid or it's derivatives in the last 30 days

          -  Underwent radiotherapy, facelift, dermabrasion, botox, or facial filler procedures in
             the last 5 years

          -  Breast lump or other breast abnormality

          -  History of cancer or malignancy

          -  Vein thrombosis

          -  History of hormonal contraception allergy

          -  History of ovariectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine, Universitas Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Shannaz Nadia Yusharyahya</investigator_full_name>
    <investigator_title>Head of Geriatric Dermatology Division, Department of Dermatovenereology, Faculty of Medicine, Indonesia University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunscreening Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

